[1]
Alexander DJ. An overview of the epidemiology of avian influenza. Vaccine. 2007 Jul 26:25(30):5637-44
[PubMed PMID: 17126960]
Level 3 (low-level) evidence
[2]
Lazarus R, Lim PL. Avian influenza: recent epidemiology, travel-related risk, and management. Current infectious disease reports. 2015 Jan:17(1):456. doi: 10.1007/s11908-014-0456-3. Epub
[PubMed PMID: 25475382]
[3]
Rabadan R, Robins H. Evolution of the influenza a virus: some new advances. Evolutionary bioinformatics online. 2008 Jan 30:3():299-307
[PubMed PMID: 19430605]
Level 3 (low-level) evidence
[4]
Lai S, Qin Y, Cowling BJ, Ren X, Wardrop NA, Gilbert M, Tsang TK, Wu P, Feng L, Jiang H, Peng Z, Zheng J, Liao Q, Li S, Horby PW, Farrar JJ, Gao GF, Tatem AJ, Yu H. Global epidemiology of avian influenza A H5N1 virus infection in humans, 1997-2015: a systematic review of individual case data. The Lancet. Infectious diseases. 2016 Jul:16(7):e108-e118. doi: 10.1016/S1473-3099(16)00153-5. Epub 2016 May 17
[PubMed PMID: 27211899]
Level 2 (mid-level) evidence
[5]
Cowling BJ, Jin L, Lau EH, Liao Q, Wu P, Jiang H, Tsang TK, Zheng J, Fang VJ, Chang Z, Ni MY, Zhang Q, Ip DK, Yu J, Li Y, Wang L, Tu W, Meng L, Wu JT, Luo H, Li Q, Shu Y, Li Z, Feng Z, Yang W, Wang Y, Leung GM, Yu H. Comparative epidemiology of human infections with avian influenza A H7N9 and H5N1 viruses in China: a population-based study of laboratory-confirmed cases. Lancet (London, England). 2013 Jul 13:382(9887):129-37. doi: 10.1016/S0140-6736(13)61171-X. Epub 2013 Jun 24
[PubMed PMID: 23803488]
Level 2 (mid-level) evidence
[6]
Qin Y, Horby PW, Tsang TK, Chen E, Gao L, Ou J, Nguyen TH, Duong TN, Gasimov V, Feng L, Wu P, Jiang H, Ren X, Peng Z, Li S, Li M, Zheng J, Liu S, Hu S, Hong R, Farrar JJ, Leung GM, Gao GF, Cowling BJ, Yu H. Differences in the Epidemiology of Human Cases of Avian Influenza A(H7N9) and A(H5N1) Viruses Infection. Clinical infectious diseases : an official publication of the Infectious Diseases Society of America. 2015 Aug 15:61(4):563-71. doi: 10.1093/cid/civ345. Epub 2015 May 4
[PubMed PMID: 25940354]
Level 2 (mid-level) evidence
[7]
Kumlin U, Olofsson S, Dimock K, Arnberg N. Sialic acid tissue distribution and influenza virus tropism. Influenza and other respiratory viruses. 2008 Sep:2(5):147-54. doi: 10.1111/j.1750-2659.2008.00051.x. Epub
[PubMed PMID: 19453419]
[8]
Belser JA, Lash RR, Garg S, Tumpey TM, Maines TR. The eyes have it: influenza virus infection beyond the respiratory tract. The Lancet. Infectious diseases. 2018 Jul:18(7):e220-e227. doi: 10.1016/S1473-3099(18)30102-6. Epub 2018 Feb 21
[PubMed PMID: 29477464]
[9]
Beigel JH, Farrar J, Han AM, Hayden FG, Hyer R, de Jong MD, Lochindarat S, Nguyen TK, Nguyen TH, Tran TH, Nicoll A, Touch S, Yuen KY, Writing Committee of the World Health Organization (WHO) Consultation on Human Influenza A/H5. Avian influenza A (H5N1) infection in humans. The New England journal of medicine. 2005 Sep 29:353(13):1374-85
[PubMed PMID: 16192482]
[10]
Zhuang J, Zang N, Ye C, Xu F. Lethal avian influenza A (H5N1) virus induces ataxic breathing in mice with apoptosis of pre-Botzinger complex neurons expressing neurokinin-1 receptor. American journal of physiology. Lung cellular and molecular physiology. 2017 Nov 1:313(5):L772-L780. doi: 10.1152/ajplung.00145.2017. Epub 2017 Jul 20
[PubMed PMID: 28729347]
[11]
Peacock THP, James J, Sealy JE, Iqbal M. A Global Perspective on H9N2 Avian Influenza Virus. Viruses. 2019 Jul 5:11(7):. doi: 10.3390/v11070620. Epub 2019 Jul 5
[PubMed PMID: 31284485]
Level 3 (low-level) evidence
[12]
Zhou L, Chen E, Bao C, Xiang N, Wu J, Wu S, Shi J, Wang X, Zheng Y, Zhang Y, Ren R, Greene CM, Havers F, Iuliano AD, Song Y, Li C, Chen T, Wang Y, Li D, Ni D, Zhang Y, Feng Z, Uyeki TM, Li Q. Clusters of Human Infection and Human-to-Human Transmission of Avian Influenza A(H7N9) Virus, 2013-2017. Emerging infectious diseases. 2018 Feb:24(2):397-400. doi: 10.3201/eid2402.171565. Epub 2018 Feb 17
[PubMed PMID: 29165238]
[13]
Chen Y, Wang D, Zheng S, Shu Y, Chen W, Cui D, Li J, Yu H, Wang Y, Li L, Shang H. Rapid diagnostic tests for identifying avian influenza A(H7N9) virus in clinical samples. Emerging infectious diseases. 2015 Jan:21(1):87-90. doi: 10.3201/eid2101.140247. Epub
[PubMed PMID: 25529064]
[14]
Schünemann HJ, Hill SR, Kakad M, Bellamy R, Uyeki TM, Hayden FG, Yazdanpanah Y, Beigel J, Chotpitayasunondh T, Del Mar C, Farrar J, Tran TH, Ozbay B, Sugaya N, Fukuda K, Shindo N, Stockman L, Vist GE, Croisier A, Nagjdaliyev A, Roth C, Thomson G, Zucker H, Oxman AD, WHO Rapid Advice Guideline Panel on Avian Influenza. WHO Rapid Advice Guidelines for pharmacological management of sporadic human infection with avian influenza A (H5N1) virus. The Lancet. Infectious diseases. 2007 Jan:7(1):21-31
[PubMed PMID: 17182341]
[15]
Herbinger KH, von Sonnenburg F, Nothdurft HD, Perona P, Borkowski A, Fragapane E, Nicolay U, Clemens R. A phase II study of an investigational tetravalent influenza vaccine formulation combining MF59®: adjuvanted, pre-pandemic, A/H5N1 vaccine and trivalent seasonal influenza vaccine in healthy adults. Human vaccines & immunotherapeutics. 2014:10(1):92-9. doi: 10.4161/hv.26495. Epub 2013 Sep 20
[PubMed PMID: 24047817]
[16]
Vaughn DW, Seifert H, Hepburn A, Dewe W, Li P, Drame M, Cohet C, Innis BL, Fries LF. Safety of AS03-adjuvanted inactivated split virion A(H1N1)pdm09 and H5N1 influenza virus vaccines administered to adults: pooled analysis of 28 clinical trials. Human vaccines & immunotherapeutics. 2014:10(10):2942-57. doi: 10.4161/21645515.2014.972149. Epub 2014 Nov 21
[PubMed PMID: 25483467]
[17]
Feldstein LR, Matrajt L, Elizabeth Halloran M, Keitel WA, Longini IM Jr, H5N1 Vaccine Working Group. Extrapolating theoretical efficacy of inactivated influenza A/H5N1 virus vaccine from human immunogenicity studies. Vaccine. 2016 Jul 19:34(33):3796-802. doi: 10.1016/j.vaccine.2016.05.067. Epub 2016 Jun 20
[PubMed PMID: 27268778]
[18]
Khurana S, Coyle EM, Manischewitz J, King LR, Gao J, Germain RN, Schwartzberg PL, Tsang JS, Golding H, and the CHI Consortium. AS03-adjuvanted H5N1 vaccine promotes antibody diversity and affinity maturation, NAI titers, cross-clade H5N1 neutralization, but not H1N1 cross-subtype neutralization. NPJ vaccines. 2018:3():40. doi: 10.1038/s41541-018-0076-2. Epub 2018 Oct 1
[PubMed PMID: 30302282]
[19]
Baz M, Luke CJ, Cheng X, Jin H, Subbarao K. H5N1 vaccines in humans. Virus research. 2013 Dec 5:178(1):78-98. doi: 10.1016/j.virusres.2013.05.006. Epub 2013 May 28
[PubMed PMID: 23726847]
[20]
Bailey ES, Fieldhouse JK, Choi JY, Gray GC. A Mini Review of the Zoonotic Threat Potential of Influenza Viruses, Coronaviruses, Adenoviruses, and Enteroviruses. Frontiers in public health. 2018:6():104. doi: 10.3389/fpubh.2018.00104. Epub 2018 Apr 9
[PubMed PMID: 29686984]